Related Experiment Video

Updated: Jul 6, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current

Aysan Moeinafshar1,2, Mohammad Nouri3, Nima Shokrollahi3

  • 1Center for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Cancer Cell International
|January 10, 2024
PubMed

Insights

Receptor tyrosine kinase regulatory non-coding RNAs (RTK-RNAs) show promise in regulating cancer pathways. Further research is needed to overcome challenges for their use as cancer biomarkers and therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Receptor tyrosine kinases (RTKs) are crucial in cancer development.
  • Non-coding RNAs (nc-RNAs) regulate gene expression, including RTKs.
  • RTK-RNAs are a class of nc-RNAs involved in RTK regulation.

Purpose of the Study:

  • To review the current research on RTK-RNAs in solid tumors.
  • To explore molecular mechanisms of RTK-RNA action.
  • To highlight advancements in RTK-RNA therapeutics and biomarker potential.

Main Methods:

  • Comprehensive literature review of in vitro, in vivo, and clinical studies.
  • Analysis of molecular mechanisms modulating RTK signaling pathways.
  • Evaluation of potential therapeutic strategies and biomarker applications.

Main Results:

  • Identification of novel RTK-RNAs and their regulatory roles.
  • Demonstration of RTK-RNA potential in modulating RTK signaling.
  • Exploration of RTK-RNAs as diagnostic, prognostic, and therapeutic targets.

Conclusions:

  • RTK-RNAs hold significant potential as therapeutic targets and biomarkers in solid tumors.
  • Challenges remain in developing targeted RTK-RNA therapies, including off-target effects.
  • Further validation in clinical settings is essential to realize the full potential of RTK-RNAs.
Keywords:
RTK-RNAsReceptor tyrosine kinaseSolid tumorscircRNAlncRNAmiRNA

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

323
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K